[
  {
    "ts": null,
    "headline": "GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises",
    "summary": "GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.",
    "url": "https://finnhub.io/api/news?id=2fe908c5d00ee70597cedb686fbcd1f93ca004941ac6b1547d0001f88728beb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753894260,
      "headline": "GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises",
      "id": 136149066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.",
      "url": "https://finnhub.io/api/news?id=2fe908c5d00ee70597cedb686fbcd1f93ca004941ac6b1547d0001f88728beb2"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare raises annual profit forecast on smaller tariff impact",
    "summary": "GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April.",
    "url": "https://finnhub.io/api/news?id=431170e5657657b5d4701165859a399a5d20348b6c767c9a049ad8c9454f9d2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753875150,
      "headline": "GE HealthCare raises annual profit forecast on smaller tariff impact",
      "id": 136129712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April.",
      "url": "https://finnhub.io/api/news?id=431170e5657657b5d4701165859a399a5d20348b6c767c9a049ad8c9454f9d2e"
    }
  },
  {
    "ts": null,
    "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
    "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
    "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753866720,
      "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
      "id": 136129851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
      "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200"
    }
  }
]